{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:17:12Z","timestamp":1791256632860,"version":"4.1.0"},"reference-count":148,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,6]],"date-time":"2023-08-06T00:00:00Z","timestamp":1691280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.apsb.2023.08.004","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T21:42:50Z","timestamp":1691530970000},"page":"87-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors"],"prefix":"10.1016","volume":"14","author":[{"given":"Letian","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghua","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mianling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongwei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Peng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1251-6640","authenticated-orcid":false,"given":"Luis","family":"Men\u00e9ndez-Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4898-7882","authenticated-orcid":false,"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7168-613X","authenticated-orcid":false,"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2023.08.004_bib1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.08.004_bib2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.apsb.2023.08.004_bib3","unstructured":"World Health Organization. WHO coronavirus (COVID-19) dashboard. Available from: https:\/\/covid19.who.int\/."},{"key":"10.1016\/j.apsb.2023.08.004_bib4","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3349\/ymj.2021.62.11.961","article-title":"SARS-CoV-2 variants of concern","volume":"62","author":"Choi","year":"2021","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.apsb.2023.08.004_bib5","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift","volume":"602","author":"Cameroni","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.08.004_bib6","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and covid-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2023.08.004_bib7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1021\/acs.jcim.1c01451","article-title":"Omicron variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance","volume":"62","author":"Chen","year":"2022","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.apsb.2023.08.004_bib8","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.3390\/molecules27082523","article-title":"Advances in the development of SARS-CoV-2 Mpro inhibitors","volume":"27","author":"Agost-Beltr\u00e1n","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2023.08.004_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113201","article-title":"RNA-dependent RNA polymerase (RdRp) inhibitors: the current landscape and repurposing for the COVID-19 pandemic","volume":"213","author":"Tian","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib10","article-title":"Molnupiravir and its antiviral activity against COVID-19","volume":"4","author":"Tian","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2023.08.004_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2055-6640(20)30016-9","article-title":"A review of the safety of favipiravir\u2013a potential treatment in the COVID-19 pandemic?.","volume":"6","author":"Pilkington","year":"2020","journal-title":"J Virus Erad"},{"key":"10.1016\/j.apsb.2023.08.004_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02479-20","article-title":"AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in\u00a0vitro and a promising oral antiviral for treatment of COVID-19","volume":"65","author":"Good","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2023.08.004_bib13","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2023.08.004_bib14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.apsb.2021.08.027","article-title":"Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors","volume":"12","author":"Gao","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.08.004_bib15","unstructured":"Clinical trials arena. Atea's AT-527 fails to meet primary goal of Phase II Covid-19 trial. Available from: https:\/\/www.clinicaltrialsarena.com\/news\/atea-at-527-primary-goal\/."},{"key":"10.1016\/j.apsb.2023.08.004_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103663","article-title":"Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: one + zero equals two?.","volume":"74","author":"Eloy","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.apsb.2023.08.004_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112517","article-title":"RdRp inhibitors and COVID-19: is molnupiravir a good option?.","volume":"146","author":"Hashemian","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2023.08.004_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100794","article-title":"An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment","volume":"59","author":"Dro\u017cd\u017cal","year":"2021","journal-title":"Drug Resist Updates"},{"key":"10.1016\/j.apsb.2023.08.004_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.616341","article-title":"Recent progress in the drug development targeting SARS-CoV-2 main protease as treatment for COVID-19","volume":"7","author":"Cui","year":"2020","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.apsb.2023.08.004_bib20","unstructured":"Simcere. XIANNUOXIN is put into production and launched today, contributing to China's economic development and the public's health. Available from: http:\/\/en.simcere.com\/news\/detail.aspx?mtt=328.."},{"key":"10.1016\/j.apsb.2023.08.004_bib21","series-title":"Keto-amide derivative and application thereof in treatment of coronavirus infection","author":"Chen","year":"2023"},{"key":"10.1016\/j.apsb.2023.08.004_bib22","unstructured":"Shionogi. Xocova\u00ae (ensitrelvir fumaric acid) tablets 125 mg aapproved in Japan for the treatment of SARS-CoV-2 iinfection, under the emergency regulatory approval system. Available from: https:\/\/www.shionogi.com\/us\/en\/news\/2022\/11\/xocova-ensitrelvir-fumaric-acid-tablets-125mg-approved-in-japan-for-the-treatment-of-sars-cov-2-infection,-under-the-emergency-regulatory-approval-system.html."},{"key":"10.1016\/j.apsb.2023.08.004_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115491","article-title":"The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022","volume":"257","author":"Pang","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3390\/ijms23010259","article-title":"A review of the current landscape of SARS-CoV-2 main protease inhibitors: have we hit the bullseye yet?","volume":"23","author":"Macip","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2023.08.004_bib25","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3390\/biom11040607","article-title":"SARS-CoV-2 Mpro: a potential target for peptidomimetics and small-molecule inhibitors","volume":"11","author":"Citarella","year":"2021","journal-title":"Biomolecules"},{"issue":"1 Pt 2","key":"10.1016\/j.apsb.2023.08.004_bib26","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.ygeno.2020.09.059","article-title":"Genetics and genomics of SARS-CoV-2: a review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection","volume":"113","author":"Rahimi","year":"2021","journal-title":"Genomics"},{"key":"10.1016\/j.apsb.2023.08.004_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: an overview of their replication and pathogenesis","volume":"1282","author":"Fehr","year":"2015","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.apsb.2023.08.004_bib28","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.08.004_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2020.104502","article-title":"From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses","volume":"85","author":"Kirtipal","year":"2020","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.apsb.2023.08.004_bib30","doi-asserted-by":"crossref","first-page":"D624","DOI":"10.1093\/nar\/gkx1134","article-title":"The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database","volume":"46","author":"Rawlings","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2023.08.004_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.948553","article-title":"Structural similarities between SARS-CoV2 3CLpro and other viral proteases suggest potential lead molecules for developing broad spectrum antivirals","volume":"10","author":"Bafna","year":"2022","journal-title":"Front Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105360","article-title":"Conserved coronavirus proteins as targets of broad-spectrum antivirals","volume":"204","author":"Melo-Filho","year":"2022","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2023.08.004_bib33","doi-asserted-by":"crossref","first-page":"442","DOI":"10.2174\/1568026620666201207095117","article-title":"An updated review on SARS-CoV-2 main proteinase (Mpro): protein structure and small-molecule inhibitors","volume":"21","author":"Sabbah","year":"2021","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib34","doi-asserted-by":"crossref","first-page":"17365","DOI":"10.1074\/jbc.AC120.016154","article-title":"Unusual zwitterionic catalytic site of SARS-CoV-2 main protease revealed by neutron crystallography","volume":"295","author":"Kneller","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib35","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.drudis.2020.12.005","article-title":"Potential SARS-CoV-2 main protease inhibitors","volume":"26","author":"Banerjee","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2023.08.004_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2020.11.024","article-title":"Structural insights into SARS-CoV-2 proteins","volume":"433","author":"Arya","year":"2021","journal-title":"J Mol Biol"},{"key":"10.1016\/j.apsb.2023.08.004_bib37","article-title":"Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2","volume":"119","author":"Zhao","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2023.08.004_bib38","doi-asserted-by":"crossref","first-page":"7261","DOI":"10.1039\/D0CP05714B","article-title":"A crystallography-based investigation of weak interactions for drug design against COVID-19","volume":"23","author":"Sepay","year":"2021","journal-title":"Phys Chem Chem Phys"},{"key":"10.1016\/j.apsb.2023.08.004_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77794-5","article-title":"Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"10","author":"Shitrit","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2023.08.004_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105744","article-title":"Importance of glutamine 189 flexibility in SARS-CoV-2 main protease: lesson learned from in silico virtual screening of ChEMBL database and molecular dynamics","volume":"160","author":"Said","year":"2021","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.apsb.2023.08.004_bib41","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejmech.2018.10.010","article-title":"A road map for prioritizing warheads for cysteine targeting covalent inhibitors","volume":"160","author":"\u00c1br\u00e1nyi-Balogh","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib42","doi-asserted-by":"crossref","first-page":"9376","DOI":"10.1021\/acs.jmedchem.2c00636","article-title":"Small-molecule thioesters as SARS-CoV-2 main protease inhibitors: enzyme inhibition, structure\u2013activity relationships, antiviral activity, and X-ray structure determination","volume":"65","author":"Pillaiyar","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib43","article-title":"MPI8 is potent against SARS-CoV-2 by inhibiting dually and delectively the SARS-CoV-2 main protease and the host Cathepsin L","volume":"17","author":"Ma","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.apsb.2023.08.004_bib44","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","volume":"613","author":"Iketani","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.08.004_bib45","article-title":"H172Y mutation perturbs the S1 pocket and nirmatrelvir binding of SARS-CoV-2 main protease through a nonnative hydrogen bond","author":"de Oliveira","year":"2022","journal-title":"Research square"},{"key":"10.1016\/j.apsb.2023.08.004_bib46","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1111\/febs.12936","article-title":"From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design","volume":"281","author":"Hilgenfeld","year":"2014","journal-title":"FEBS J"},{"key":"10.1016\/j.apsb.2023.08.004_bib47","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1021\/acscombsci.0c00058","article-title":"Targeting the dimerization of the main protease of coronaviruses: a potential broad-spectrum therapeutic strategy","volume":"22","author":"Goyal","year":"2020","journal-title":"ACS Comb Sci"},{"key":"10.1016\/j.apsb.2023.08.004_bib48","first-page":"1","article-title":"Inhibition of SARS-CoV-2 main protease: a repurposing study that targets the dimer interface of the protein","volume":"13","author":"Pekel","year":"2021","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.apsb.2023.08.004_bib49","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s42003-022-03084-7","article-title":"Modulation of the monomer-dimer equilibrium and catalytic activity of SARS-CoV-2 main protease by a transition-state analog inhibitor","volume":"5","author":"Nashed","year":"2022","journal-title":"Commun Biol"},{"issue":"Pt 3","key":"10.1016\/j.apsb.2023.08.004_bib50","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1107\/S2059798322000948","article-title":"A new inactive conformation of SARS-CoV-2 main protease","volume":"78","author":"Fornasier","year":"2022","journal-title":"Acta Crystallogr D Struct Biol"},{"key":"10.1016\/j.apsb.2023.08.004_bib51","doi-asserted-by":"crossref","first-page":"6553","DOI":"10.1021\/acs.jcim.2c00693","article-title":"Structure-based identification of naphthoquinones and derivatives as novel inhibitors of main protease Mpro and papain-like protease PLpro of SARS-CoV-2","volume":"62","author":"Santos","year":"2022","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.apsb.2023.08.004_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128067","article-title":"Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library","volume":"42","author":"Lee","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2023.08.004_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.661424","article-title":"An integrated computational and experimental approach to identifying inhibitors for SARS-CoV-2 3CL protease","volume":"8","author":"Zhai","year":"2021","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.apsb.2023.08.004_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105350","article-title":"Discovery of novel SARS-CoV-2 inhibitors targeting the main protease Mpro by virtual screenings and hit optimization","volume":"204","author":"Mercorelli","year":"2022","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2023.08.004_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012235","article-title":"Anticoagulants as potential SARS-CoV-2 Mpro inhibitors for COVID-19 patients: in\u00a0vitro, molecular docking, molecular dynamics, DFT, and SAR studies","volume":"23","author":"Abo Elmaaty","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2023.08.004_bib56","article-title":"Bepridil is potent against SARS-CoV-2 in\u00a0vitro","volume":"18","author":"Vatansever","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2023.08.004_bib57","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1021\/jacs.1c08402","article-title":"Ultralarge virtual screening identifies SARS-CoV-2 main protease inhibitors with broad-spectrum activity against coronaviruses","volume":"144","author":"Luttens","year":"2022","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2023.08.004_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.102021","article-title":"A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening","volume":"24","author":"Gorgulla","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.apsb.2023.08.004_bib59","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1038\/s41598-022-06306-4","article-title":"Non-covalent SARS-CoV-2 Mpro inhibitors developed from in silico screen hits","volume":"12","author":"Rossetti","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2023.08.004_bib60","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1021\/acs.jcim.1c00851","article-title":"High-throughput virtual screening and validation of a SARS-CoV-2 main protease noncovalent inhibitor","volume":"62","author":"Clyde","year":"2022","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.apsb.2023.08.004_bib61","doi-asserted-by":"crossref","first-page":"17366","DOI":"10.1021\/acs.jmedchem.1c01475","article-title":"Structural, electronic, and electrostatic determinants for inhibitor binding to subsites S1 and S2 in SARS-CoV-2 main protease","volume":"64","author":"Kneller","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib62","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1021\/acs.jmedchem.1c01372","article-title":"Efficient identification of anti-SARS-CoV-2 compounds using chemical structure- and biological activity-based modeling","volume":"65","author":"Xu","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib63","doi-asserted-by":"crossref","first-page":"15960","DOI":"10.1039\/D1SC05579H","article-title":"Automated discovery of noncovalent inhibitors of SARS-CoV-2 main protease by consensus deep docking of 40 billion small molecules","volume":"12","author":"Gentile","year":"2021","journal-title":"Chem Sci"},{"key":"10.1016\/j.apsb.2023.08.004_bib64","article-title":"An enhanced hybrid screening approach to identify potent inhibitors for the SARS-CoV-2 main protease from the NCI compound library","volume":"10","author":"Li","year":"2022","journal-title":"Front Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib65","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3390\/ijms20061375","article-title":"The light and dark sides of virtual screening: what is there to know?.","volume":"20","author":"Gimeno","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2023.08.004_bib66","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/med.21862","article-title":"Haste makes waste: a critical review of docking-based virtual screening in drug repurposing for SARS-CoV-2 main protease (M-pro) inhibition","volume":"42","author":"Macip","year":"2022","journal-title":"Med Res Rev"},{"key":"10.1016\/j.apsb.2023.08.004_bib67","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41589-022-01234-w","article-title":"Modeling the expansion of virtual screening libraries","volume":"19","author":"Lyu","year":"2023","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2023.08.004_bib68","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.apsb.2023.08.004_bib69","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.08.004_bib70","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1177\/24725552211020681","article-title":"Efficiency improvements and discovery of new substrates for a SARS-CoV-2 main protease FRET assay","volume":"26","author":"Dra\u017ei\u0107","year":"2021","journal-title":"SLAS Discov"},{"key":"10.1016\/j.apsb.2023.08.004_bib71","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1021\/acs.jmedchem.2c00303","article-title":"Progress and challenges in targeting the SARS-CoV-2 papain-like protease","volume":"65","author":"Tan","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib72","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.3390\/molecules25204666","article-title":"High-throughput screening for inhibitors of the SARS-CoV-2 protease using a FRET-biosensor","volume":"25","author":"Brown","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2023.08.004_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202200190","article-title":"Luminescent assay for the screening of SARS-CoV-2 Mpro inhibitors","volume":"23","author":"Sondag","year":"2022","journal-title":"Chembiochem"},{"key":"10.1016\/j.apsb.2023.08.004_bib74","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.apsb.2021.10.026","article-title":"Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays","volume":"12","author":"Ma","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.08.004_bib75","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1177\/2472555220963667","article-title":"High throughput screening for drugs that inhibit 3C-like protease in SARS-CoV-2","volume":"25","author":"Smith","year":"2020","journal-title":"SLAS Discov"},{"key":"10.1016\/j.apsb.2023.08.004_bib76","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1021\/acsptsci.0c00108","article-title":"Identification of SARS-CoV-2 3CL protease inhibitors by a quantitative high-throughput screening","volume":"3","author":"Zhu","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.apsb.2023.08.004_bib77","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12033-021-00299-7","article-title":"Cell-based high-throughput screening protocol for discovering antiviral inhibitors against SARS-CoV-2 main protease (3CLpro)","volume":"63","author":"Rothan","year":"2021","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.apsb.2023.08.004_bib78","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1126\/science.abg5827","article-title":"Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2","volume":"373","author":"Drayman","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.apsb.2023.08.004_bib79","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1021\/acscentsci.2c01359","article-title":"Development of highly potent non-covalent inhibitors of SARS-CoV-2 3CLpro","volume":"9","author":"Hou","year":"2023","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.apsb.2023.08.004_bib80","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/s41467-023-37071-1","article-title":"Trio-pharmacophore DNA-encoded chemical library for simultaneous selection of fragments and linkers","volume":"14","author":"Cui","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2023.08.004_bib81","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3390\/v13020174","article-title":"Crystal structure of SARS-CoV-2 main protease in complex with the non-covalent inhibitor ML188","volume":"13","author":"Lockbaum","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.apsb.2023.08.004_bib82","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1021\/acs.jmedchem.1c00509","article-title":"Expedited approach toward the rational design of noncovalent SARS-CoV-2 main protease inhibitors","volume":"65","author":"Kitamura","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib83","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41564-022-01119-7","article-title":"An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron","volume":"7","author":"Quan","year":"2022","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.apsb.2023.08.004_bib84","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/ph15081021","article-title":"A versatile class of 1,4,4-trisubstituted piperidines block coronavirus replication in\u00a0vitro","volume":"15","author":"De Castro","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.apsb.2023.08.004_bib85","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1021\/acsmedchemlett.0c00521","article-title":"Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2","volume":"11","author":"Ghahremanpour","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.apsb.2023.08.004_bib86","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1021\/acscentsci.1c00039","article-title":"Potent noncovalent inhibitors of the main protease of SARS-CoV-2 from molecular sculpting of the drug perampanel guided by free energy perturbation calculations","volume":"7","author":"Zhang","year":"2021","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.apsb.2023.08.004_bib87","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/acsmedchemlett.1c00326","article-title":"Optimization of triarylpyridinone inhibitors of the main protease of SARS-CoV-2 to low-nanomolar antiviral potency","volume":"12","author":"Zhang","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.apsb.2023.08.004_bib88","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.str.2021.06.002","article-title":"Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease","volume":"29","author":"Deshmukh","year":"2021","journal-title":"Structure"},{"key":"10.1016\/j.apsb.2023.08.004_bib89","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1016\/j.bmcl.2013.08.112","article-title":"Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl) acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding","volume":"23","author":"Turlington","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2023.08.004_bib90","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1021\/acs.jmedchem.1c00598","article-title":"Structure-based optimization of ML300-derived, noncovalent inhibitors targeting the severe acute respiratory syndrome coronavirus 3CL protease (SARS-CoV-2 3CLpro)","volume":"65","author":"Han","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib91","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1038\/s41467-020-18709-w","article-title":"Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease","volume":"11","author":"Douangamath","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2023.08.004_bib92","doi-asserted-by":"crossref","first-page":"13343","DOI":"10.1021\/acs.jmedchem.2c01146","article-title":"Discovery and crystallographic studies of trisubstituted piperazine derivatives as non-covalent SARS-CoV 2 main protease inhibitors with high target specificity and low toxicity","volume":"65","author":"Gao","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib93","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib94","doi-asserted-by":"crossref","first-page":"6496","DOI":"10.1021\/acs.jmedchem.2c00624","article-title":"S-217622, a 3CL protease inhibitor and clinical candidate for SARS-CoV-2","volume":"65","author":"Tyndall","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib95","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1093\/jac\/dkac257","article-title":"Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model","volume":"77","author":"Nobori","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2023.08.004_bib96","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq4064","article-title":"S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters","volume":"15","author":"Sasaki","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2023.08.004_bib97","unstructured":"Shionogi. Shionogi presents phase 2\/3 clinical trial results (Phase 2a Part) for the COVID-19 therapeutic drug S-217622. Available from: https:\/\/www.shionogi.com\/global\/en\/news\/2022\/2\/e-20220207.html."},{"key":"10.1016\/j.apsb.2023.08.004_bib98","unstructured":"Shionogi. Shionogi announces achievement of the primary endpoint for ensitrelvir fumaric acid (S-217622) in the phase 3 part of the phase 2\/3 clinical trial in Asia. Available from: https:\/\/www.shionogi.com\/global\/en\/news\/2022\/09\/20220928.html.."},{"key":"10.1016\/j.apsb.2023.08.004_bib99","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.2174\/1568026621666210804115700","article-title":"Perspectives on fragment-based drug discovery: a strategy applicable to diverse targets","volume":"21","author":"Li","year":"2021","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib100","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15123","article-title":"A multi-crystal method for extracting obscured crystallographic states from conventionally uninterpretable electron density","volume":"8","author":"Pearce","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2023.08.004_bib101","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1038\/s41467-021-23443-y","article-title":"Exploring protein hotspots by optimized fragment pharmacophores","volume":"12","author":"Bajusz","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2023.08.004_bib102","doi-asserted-by":"crossref","first-page":"25428","DOI":"10.1002\/anie.202109965","article-title":"NMR spectroscopy of the main protease of SARS-CoV-2 and fragment-based screening identify three protein hotspots and an antiviral fragment","volume":"60","author":"Cantrelle","year":"2021","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2023.08.004_bib103","article-title":"Open science discovery of oral non-covalent SARS-CoV-2 main protease inhibitor therapeutics","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.apsb.2023.08.004_bib104","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2214168120","article-title":"Turning high-throughput structural biology into predictive inhibitor design","volume":"120","author":"Saar","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2023.08.004_bib105","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1039\/D1CC00050K","article-title":"Discovery of SARS-CoV-2 main protease inhibitors using a synthesis-directed de novo design model","volume":"57","author":"Morris","year":"2021","journal-title":"Chem Commun"},{"key":"10.1016\/j.apsb.2023.08.004_bib106","unstructured":"PostEra. COVID Moonshot. Available from: http:\/\/postera.ai\/covid."},{"key":"10.1016\/j.apsb.2023.08.004_bib107","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13321-022-00588-6","article-title":"Galaxy workflows for fragment-based virtual screening: a case study on the SARS-CoV-2 main protease","volume":"14","author":"Bray","year":"2022","journal-title":"J Cheminf"},{"key":"10.1016\/j.apsb.2023.08.004_bib108","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.scib.2020.10.018","article-title":"Crystal structure of SARS-CoV-2 main protease in complex with the natural product inhibitor shikonin illuminates a unique binding mode","volume":"66","author":"Li","year":"2021","journal-title":"Sci Bull"},{"key":"10.1016\/j.apsb.2023.08.004_bib109","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41401-020-0483-6","article-title":"Anti-SARS-CoV-2 activities in\u00a0vitro of Shuanghuanglian preparations and bioactive ingredients","volume":"41","author":"Su","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2023.08.004_bib110","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.ijbiomac.2020.07.235","article-title":"Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening","volume":"164","author":"Abian","year":"2020","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.apsb.2023.08.004_bib111","doi-asserted-by":"crossref","first-page":"7048","DOI":"10.3390\/ijms22137048","article-title":"Seleno-functionalization of quercetin improves the non-covalent inhibition of Mpro and its antiviral activity in cells against SARS-CoV-2","volume":"22","author":"Mangiavacchi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2023.08.004_bib112","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/513481a","article-title":"Chemistry: chemical con artists foil drug discovery","volume":"513","author":"Baell","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.08.004_bib113","doi-asserted-by":"crossref","first-page":"7646","DOI":"10.1074\/jbc.M807947200","article-title":"Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds","volume":"284","author":"Lee","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib114","doi-asserted-by":"crossref","first-page":"10083","DOI":"10.1039\/D1CC03563K","article-title":"Zinc2+ ion inhibits SARS-CoV-2 main protease and viral replication in\u00a0vitro","volume":"57","author":"Panchariya","year":"2021","journal-title":"Chem Commun"},{"key":"10.1016\/j.apsb.2023.08.004_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2022.111777","article-title":"Inhibition of SARS-CoV-2 replication by zinc gluconate in combination with hinokitiol","volume":"231","author":"Tao","year":"2022","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.apsb.2023.08.004_bib116","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1039\/D1SC06750H","article-title":"Antiviral cyclic peptides targeting the main protease of SARS-CoV-2","volume":"13","author":"Johansen-Leete","year":"2022","journal-title":"Chem Sci"},{"key":"10.1016\/j.apsb.2023.08.004_bib117","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.2147\/DDDT.S370574","article-title":"Allosteric binding sites of the SARS-CoV-2 main protease: potential targets for broad-spectrum anti-coronavirus agents","volume":"16","author":"Alzyoud","year":"2022","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.apsb.2023.08.004_bib118","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1126\/science.abf7945","article-title":"X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease","volume":"372","author":"G\u00fcnther","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.apsb.2023.08.004_bib119","doi-asserted-by":"crossref","first-page":"23750","DOI":"10.1002\/ange.202010316","article-title":"Allosteric inhibition of the SARS-CoV-2 main protease: insights from mass spectrometry based assays","volume":"132","author":"El-Baba","year":"2020","journal-title":"Angew Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib120","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1515\/BC.2002.150","article-title":"Dimerization inhibitors of HIV-1 protease","volume":"383","author":"Boggetto","year":"2002","journal-title":"Biol Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib121","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1021\/acscombsci.0c00058","article-title":"Targeting the dimerization of the main protease of coronaviruses: a potential broad-spectrum therapeutic strategy","volume":"22","author":"Goyal","year":"2020","journal-title":"ACS Comb Sci"},{"key":"10.1016\/j.apsb.2023.08.004_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2020.107372","article-title":"Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface","volume":"89","author":"Liang","year":"2020","journal-title":"Comput Biol Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib123","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1021\/acs.jcim.1c00140","article-title":"Elucidation of cryptic and allosteric pockets within the SARS-CoV-2 main protease","volume":"61","author":"Sztain","year":"2021","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.apsb.2023.08.004_bib124","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.apsb.2023.08.004_bib125","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib126","doi-asserted-by":"crossref","first-page":"11168","DOI":"10.1021\/ja3001908","article-title":"Computational discovery of picomolar Q(o) site inhibitors of cytochrome bc1 complex","volume":"134","author":"Hao","year":"2012","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2023.08.004_bib127","doi-asserted-by":"crossref","first-page":"W550","DOI":"10.1093\/nar\/gkw393","article-title":"ACFIS: a web server for fragment-based drug discovery","volume":"44","author":"Hao","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2023.08.004_bib128","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/17460441.2021.1867095","article-title":"Multi-objective optimization methods in novel drug design","volume":"16","author":"Lambrinidis","year":"2021","journal-title":"Expet Opin Drug Discov"},{"key":"10.1016\/j.apsb.2023.08.004_bib129","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111172118","article-title":"DNA-encoded chemistry technology yields expedient access to SARS-CoV-2 Mpro inhibitors","volume":"118","author":"Chamakuri","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2023.08.004_bib130","doi-asserted-by":"crossref","first-page":"18231","DOI":"10.1002\/anie.202105584","article-title":"Combining high-throughput synthesis and high-throughput protein crystallography for accelerated hit identification","volume":"60","author":"Sutanto","year":"2021","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2023.08.004_bib131","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.drudis.2015.08.004","article-title":"Discovery of bioactive molecules from CuAAC click-chemistry-based combinatorial libraries","volume":"21","author":"Wang","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2023.08.004_bib132","doi-asserted-by":"crossref","first-page":"23492","DOI":"10.1002\/anie.202107481","article-title":"Repurposing an antiviral drug against SARS-CoV-2 main protease","volume":"60","author":"Sarkar","year":"2021","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2023.08.004_bib133","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf8711","article-title":"Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking","volume":"7","author":"Schuller","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2023.08.004_bib134","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1038\/s41467-021-25166-6","article-title":"Structure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase","volume":"12","author":"Newman","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2023.08.004_bib135","doi-asserted-by":"crossref","first-page":"12256","DOI":"10.1002\/anie.201303207","article-title":"Profound methyl effects in drug discovery and a call for new C\u2013H methylation reactions","volume":"52","author":"Sch\u00f6nherr","year":"2013","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2023.08.004_bib136","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1021\/acs.jmedchem.2c02015","article-title":"Magic chloro: profound effects of the chlorine atom in drug discovery","volume":"66","author":"Chiodi","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib137","doi-asserted-by":"crossref","first-page":"605","DOI":"10.4155\/fmc-2022-0008","article-title":"HIV-1 capsid inhibitors: a sword to destroy the virus","volume":"14","author":"Zhang","year":"2022","journal-title":"Future Med Chem"},{"key":"10.1016\/j.apsb.2023.08.004_bib138","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1021\/ct200668a","article-title":"HIV-1 protease and substrate coevolution validates the substrate envelope as the substrate recognition pattern","volume":"8","author":"Ozen","year":"2012","journal-title":"J Chem Theor Comput"},{"key":"10.1016\/j.apsb.2023.08.004_bib139","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1021\/cb400468c","article-title":"Testing the substrate-envelope hypothesis with designed pairs of compounds","volume":"8","author":"Shen","year":"2013","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.apsb.2023.08.004_bib140","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1038\/s41467-022-31210-w","article-title":"Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance","volume":"13","author":"Shaqra","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2023.08.004_bib141","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.77433","article-title":"Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms","volume":"11","author":"Flynn","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.apsb.2023.08.004_bib142","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00869-22","article-title":"Genetic surveillance of SARS-CoV-2 Mpro reveals high sequence and structural conservation prior to the introduction of protease inhibitor Paxlovid","volume":"13","author":"Lee","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.apsb.2023.08.004_bib143","series-title":"Novel macrocyclic antiviral agents","author":"Zhang","year":"2022"},{"key":"10.1016\/j.apsb.2023.08.004_bib144","first-page":"199","article-title":"Multivalent inhibitors of channel-forming bacterial toxins","volume":"406","author":"Yamini","year":"2017","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.apsb.2023.08.004_bib145","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1039\/D0CS01084G","article-title":"Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses","volume":"50","author":"Ma","year":"2021","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.apsb.2023.08.004_bib146","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1038\/s41467-019-11429-w","article-title":"Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations","volume":"10","author":"De Wispelaere","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2023.08.004_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2023.100092","article-title":"Antiviral PROTACs: opportunity borne with challenge","volume":"2","author":"Liang","year":"2023","journal-title":"Cell Insight"},{"key":"10.1016\/j.apsb.2023.08.004_bib148","series-title":"PROTACS targeting coronavirus 3CL protease and preparation method and application thereof","author":"Liang","year":"2023"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383523002939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383523002939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T03:01:21Z","timestamp":1720580481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383523002939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":148,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2211383523002939"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2023.08.004","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2023.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}